Kala Pharmaceuticals ( (KALA) ) has released its Q2 earnings. Here is a breakdown of the information Kala Pharmaceuticals presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kala Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on developing innovative therapies for rare and severe eye diseases using its proprietary mesenchymal stem cell secretome (MSC-S) platform.
In its latest earnings report, Kala Pharmaceuticals highlighted the completion of patient enrollment in the Phase 2b CHASE trial for KPI-012, a treatment for Persistent Corneal Epithelial Defect (PCED), with topline data expected by the end of September 2025. The company also reported a cash position of $31.9 million as of June 30, 2025, expected to fund operations into the first quarter of 2026.
Key financial metrics for the second quarter of 2025 include an operating loss of $11.0 million and a net loss of $11.2 million, compared to $9.6 million and $9.6 million, respectively, for the same period in 2024. The increase in losses is attributed to higher research and development expenses, primarily due to KPI-012 development costs. Additionally, the company is exploring the potential of KPI-012 for other rare eye diseases, such as Limbal Stem Cell Deficiency (LSCD).
Looking ahead, Kala Pharmaceuticals is optimistic about the potential of KPI-012 to address unmet needs in PCED treatment, with the possibility of the CHASE trial serving as a pivotal study for FDA approval. The company continues to explore its MSC-S platform’s applications for other rare ocular diseases, positioning itself for future growth in the biopharmaceutical sector.